NCT03556228 2025-12-11
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1/2 Recruiting
VM Oncology, LLC
Calithera Biosciences, Inc
Bayer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Point Therapeutics